Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Serum potassium in the PARADIGM-HF trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Self-reported health status and the associated risk of mortality in heart failure: The DANISH trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Quality of life and the associated risk of all-cause mortality in nonischemic heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Association between Type D personality and outcomes in patients with non-ischemic heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • João Pedro Ferreira
  • Ulrik M Mogensen
  • Pardeep S Jhund
  • Akshay S Desai
  • Jean-Lucien Rouleau
  • Michael R Zile
  • Patrick Rossignol
  • Faiez Zannad
  • Milton Packer
  • Scott D Solomon
  • John J V McMurray
Vis graf over relationer

AIMS: The associations between potassium level and outcomes, the effect of sacubitril-valsartan on potassium level, and whether potassium level modified the effect of sacubitril-valsartan in patients with heart failure and a reduced ejection fraction were studied in PARADIGM-HF. Several outcomes, including cardiovascular death, sudden death, pump failure death, non-cardiovascular death and heart failure hospitalization, were examined.

METHODS AND RESULTS: A total of 8399 patients were randomized to either enalapril or sacubitril-valsartan. Potassium level at randomization and follow-up was examined as a continuous and categorical variable (≤3.5, 3.6-4.0, 4.1-4.9, 5.0-5.4 and ≥5.5 mmol/L) in various statistical models. Hyperkalaemia was defined as K+  ≥5.5 mmol/L and hypokalaemia as K+  ≤3.5 mmol/L. Compared with potassium 4.1-4.9 mmol/L, both hypokalaemia [hazard ratio (HR) 2.40, 95% confidence interval (CI) 1.84-3.14] and hyperkalaemia (HR 1.42, 95% CI 1.10-1.83) were associated with a higher risk for cardiovascular death. However, potassium abnormalities were similarly associated with sudden death and pump failure death, as well as non-cardiovascular death and heart failure hospitalization. Sacubitril-valsartan had no effect on potassium overall. The benefit of sacubitril-valsartan over enalapril was consistent across the range of baseline potassium levels.

CONCLUSIONS: Although both higher and lower potassium levels were independent predictors of cardiovascular death, potassium abnormalities may mainly be markers rather than mediators of risk for death.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Heart Failure
Vol/bind22
Udgave nummer11
Sider (fra-til)2056-2064
Antal sider9
ISSN1388-9842
DOI
StatusUdgivet - nov. 2020

Bibliografisk note

© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

ID: 62333211